SCHEMBL2408754

SCHEMBL2408754

CC(NS(=O)(=O)c1ccc(F)cc1)c1ccc(C(=O)NO)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPC1 O15118 1/20 0.49
MMP1 P03956 3/20 0.48
MMP2 P08253 3/20 0.48
MMP9 P14780 3/20 0.48
MMP13 P45452 3/20 0.48
MMP3 P08254 2/20 0.48
MMP7 P09237 2/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
PTGS2 P35354 1/20 0.48
HDAC8 Q9BY41 3/20 0.48
HDAC6 Q9UBN7 3/20 0.48
HDAC1 Q13547 1/20 0.48
MMP8 P22894 2/20 0.47
MMP14 P50281 1/20 0.47
POLB P06746 1/20 0.47
EPHX2 P34913 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412211 0.89 HDAC6 (0.50) ALDH1A1LMNAHDAC8HDAC6HDAC1
SCHEMBL2408067 0.88 HDAC6 (0.56) KMT2AGAAL3MBTL1MMP1MMP2
SCHEMBL2413093 0.87 MMP7 (0.52) L3MBTL1MMP1MMP2MMP9MMP13
SCHEMBL2412670 0.87 MMP7 (0.52) L3MBTL1MMP1MMP2MMP9MMP13
SCHEMBL2406959 0.86 FLT1 (0.57) L3MBTL1MMP1MMP2MMP9MMP13
SCHEMBL2412830 0.86 POLB (0.56) GAAMMP2ALDH1A1LMNAHDAC8
SCHEMBL2406521 0.86 SLC1A3 (0.47) KMT2AALDH1A1LMNAHDAC8HDAC6
SCHEMBL2408091 0.85 HDAC8 (0.64) KMT2AGAAALDH1A1HDAC8HDAC6
SCHEMBL2407258 0.84 LMNA (0.60) MMP1MMP2MMP9MMP13MMP3
SCHEMBL2409111 0.82 HDAC6 (0.44) KMT2ANPC1ALDH1A1LMNAHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US claimed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 KMT2A 137/4885GAA 252/4885L3MBTL1 2662/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 KMT2A 137/4885GAA 252/4885L3MBTL1 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.